	US 11,958,914 B2
	CAR-T cells targeting glioma stem cells for the treatment of glioblastoma multiforme
James Liu, Lutz, FL (US); and Daniel Abate-Daga, Tampa, FL (US)
Assigned to H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US)
Filed by H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US)
Filed on Jul. 12, 2022, as Appl. No. 17/811,945.
Application 17/811,945 is a continuation of application No. 17/212,320, filed on Mar. 25, 2021, granted, now 11,384,118.
Application 17/212,320 is a continuation in part of application No. PCT/US2019/053793, filed on Sep. 30, 2019.
Claims priority of provisional application 62/739,579, filed on Oct. 1, 2018.
Prior Publication US 2023/0038996 A1, Feb. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/00 (2006.01); A61K 35/17 (2015.01); C07K 7/06 (2006.01); C07K 16/28 (2006.01)

CPC C07K 7/06 (2013.01) [A61K 35/17 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)]

14 Claims

1. A polypeptide, comprising a Glioblastoma Stem Cells (GSC) antigen binding domain, a transmembrane domain, a co-stimulatory signaling region, and optionally an intracellular signaling domain, wherein the GSC antigen binding domain is a polypeptide selected from the group consisting of

(SEQ ID NO: 15)
SSQPFWS-GGGGSGGGGSGGGGS-AWEFYFP-GSTSGSGKPGSGEGSTKG

(SEQ ID NO: 17)
AWEFYFP-GGGGSGGGGSGGGGS-SSQPFWS-GSTSGSGKPGSGEGSTKG

(SEQ ID NO: 19)
AWTTTFP-GGGGSGGGGSGGGGS-SSQPFWS-GSTSGSGKPGSGEGSTKG.

(SEQ ID NO: 21)
AWTWTLP-GGGGSGGGGSGGGGS-SSQPFWS-GSTSGSGKPGSGEGSTKG

(SEQ ID NO: 23)
EWLFSMP-GGGGSGGGGSGGGGS-SSQPFWS-GSTSGSGKPGSGEGSTKG

(SEQ ID NO: 25)
GWFYTFP-GGGGSGGGGSGGGGS-SSQPFWS-GSTSGSGKPGSGEGSTKG

(SEQ ID NO: 27)
NWYWVYP-GGGGSGGGGSGGGGS-SSQPFWS-GSTSGSGKPGSGEGSTKG.